Chesterford Research Park

Arecor presents positive data from Phase I Clinical Trial of ultra-concentrated ultra-rapid acting insulin AT278

12/09/2024

Arecor Therapeutics today presents positive results from its Phase I clinical trial of the ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in Type 2 diabetics with a high body mass index (BMI).

Healx announces $47 million Series C financing and FDA clearance of phase 2 IND for Neurofibromatosis type 1 trial

09/08/2024

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, announced it has raised $47 million in a Series C round.

Peter Campbell named CSO at Quotient Therapeutics

09/08/2024

Renowned scientist Peter Campbell has become Chief Scientific Officer of Cambridge UK and US somatic genomics company Quotient Therapeutics.

CellCentric’s $60m raise for Phase III readiness and set-up in US

02/08/2024

CellCentric has secured the three invesments which total more than $60m.

CellCentric Secures $35 Million Investment from RA Capital Management

01/08/2024

CellCentric announces that it has secured a $35 million investment from RA Capital Management.

Sweetness in Seattle: PartitionBio wins Gates Foundation support

01/08/2024

PartitionBio has secured $480,500 from the Gates Foundation in Seattle to develop a platform to unlock previously undruggable targets.

Arecor raises £6.26m to underpin fresh push for growth

24/07/2024

Quoted Cambridge biopharma company Arecor Therapeutics plc has raised £6.26 million to fend off a cash crisis that could have threatened its survival.

Chesterford Research Park appoints Glencar to continue construction of 60,000 sq ft Sidney Sussex Building

05/06/2024

Three-storey, multi-occupancy building on track to provide fully fitted laboratory suites for fast-growing life science community within the Cambridge cluster.

AT278 ultra-concentrated ultra-rapid acting insulin demonstrates superiority in Phase I Clinical Trial in overweight and obese people with type 2 diabetes

20/05/2024

AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI.

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

09/05/2024

Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump.

Broken String Biosciences to collaborate with Francis Crick Institute on ALS goal

08/05/2024

Broken String Biosciences is partnering with the Francis Crick Institute to advance amyotrophic lateral sclerosis (ALS) research.

Arecor and TRx Biosciences Establish Research Collaboration to Develop Oral GLP-1 with Enhanced Bioavailability

12/03/2024

Arecor and TRx Biosciences announced a research collaboration for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.

Superdielectrics Launches the Faraday 1

11/03/2024

The Company is formally launching the Faraday 1, its state-of-the-art hybrid energy storage technology.

Arecor announces update on INBRX-101

25/01/2024

Arecor notes the news announced today from Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) that the companies have entered into a definitive agreement under which Sanofi will acquire all the assets and liabilities associated with INBRX‐101.

Arecor granted key european patent extending protection for insulin products, AT278 and AT247

25/01/2024

Arecor Therapeutics is pleased to announce that the European Patent Office has granted a patent (EP3618840) protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247.

Arecor announces expansion of existing specialty hospital formulation collaboration

08/01/2024

Arecor Therapeutics today announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies.

Arecor appoints Dr Helen Parris as Senior Vice President, Commercial And General Manager of Tetris Pharma Ltd

08/01/2024

Arecor Therapeutics is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pharma, effective Monday 15 January 2024.

Arecor signs agreement with global medical products company

04/12/2023

Arecor Therapeutic today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline.

Arecor continues collaboration with Lilly

30/11/2023

Arecor Therapeutics today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).

Chesterford Research Park begins construction of 60,000 sq ft fossil fuel free Sidney Sussex Building

20/11/2023

New 60,000 sq ft multi-occupancy building will provide additional space for life science companies within Cambridge cluster.

First product incorporating Arecor’s Arestat Technology, AT220, launches in Europe

17/11/2023

Arecor Therapeutics announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a product, AT220, incorporating its proprietary Arestat™ technology platform.

Inhibrx milestone triggers payment to Arecor under license agreement

03/11/2023

Arecor Therapeutics announces the triggering of a milestone payment from Inhibrx Inc.

Broken String Biosciences Closes $15M Series A Funding Round

18/09/2023

Broken String Biosciences today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners.

Arecor announces positive pre-IND meeting with FDA for novel ready-to-use medicine AT307 licensed to Hikma

07/09/2023

Arecor Therapeutics is pleased to announce further progress from Hikma in the development of ready-to-use ("RTU") injectable medicine AT307.

Arecor to Collaborate with Top 10 Global Pharmaceutical Company

17/08/2023

Arecor Therapeutics today announces that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs.

Breaking Ground: Opportunities in life-sciences real estate

08/08/2023

An exploration of the key drivers of growth in the UK and European life sciences sector.

University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments

01/08/2023

Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.

Cambridge genomics pioneer Constructive Bio unveils gene synthesis breakthrough

24/07/2023

Cambridge synthetic biology pioneer Constructive Bio, which accelerated out of stealth with $15 million seed cash last year, has made significant advances with its next generation genome synthesis technology, CONEXER.

NodThera is First to Demonstrate Reduction in Neuroinflammation

13/07/2023

NodThera today announces positive, initial data from four subjects in the elderly volunteer stage of its Phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).

CellCentric announces $25m strategic investment from Pfizer

13/07/2023

CellCentric today announces a strategic investment from Pfizer including $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer.

Arecor Presents Positive Data from US Phase I Clinical Trial of Ultra-Rapid Acting Insulin Candidate AT247

05/07/2023

Arecor Therapeutics today announces that positive results from its second Phase I clinical trial investigating ultra-rapid acting insulin product candidate, AT247, have been shared in a poster presentation at the American Diabetes Association (ADA) 83rd Scientific Sessions meeting.

Arecor Announces Additional Agreement with Leading Biopharmaceutical Company

05/07/2023

Arecor Therapeutics announces that it has entered into an agreement with a leading biopharmaceutical company to support the ongoing development of a biosimilar product.

Arecor Granted Key Patents in Europe and China to Protect Proprietary Insulin Products

05/07/2023

Arecor Therapeutics is pleased to announce that the European Patent Office has granted a key patent (EP3518892), protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247.

Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases

04/07/2023

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announces it has closed a $10m Series A financing round, led by Mercia.

CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma

15/06/2023

CellCentric today announces that the US Food and Drug Administration (FDA) has granted its novel cancer drug inobrodib Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma.

Future Materials Group Acquires Counterpoint Market Intelligence

14/06/2023

Future Materials Group (FMG) announced today the successful acquisition of Counterpoint Market Intelligence Ltd, a respected market intelligence and consulting company focused on the aerospace and defence markets.

US Patent Granted Protecting Proprietary Formulations of Monoclonal Antibodies

27/04/2023

Arecor Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11608357) protecting a novel formulation platform that enables the development of enhanced monoclonal antibodies.

Domainex secures a prestigious King’s Award for Enterprise

21/04/2023

Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period.

biomodal launches solution to simultaneously sequence genetics and epigenetics in one workflow

17/04/2023

biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample.

Microbiotica Announces Clinical Trial Collaboration with MSD

13/04/2023

Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA).

Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship

06/04/2023

The relationship between Isogenica and the Frederick National Laboratory for Cancer Research grows stronger as the start of two more projects are announced.

Arecor Appoints Dr. Manjit Rahelu as Chief Business Officer

05/04/2023

Arecor Therapeutics announces the appointment of Dr. Manjit Rahelu as Chief Business Officer, with immediate effect.

First Patient Dosed in Second Phase I Clinical Trial of AT278 Ultra-concentrated, Ultra-rapid acting Insulin Candidate

05/04/2023

Arecor Therapeutics announces that the first patient has been dosed in its Phase I clinical trial investigating AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population.

Arecor announces publication of Phase I data for AT278 in diabetes care

31/01/2023

Arecor Therapeutics today announces that the American Diabetes Association journal, Diabetes Care, has published data from the Company’s Phase I clinical trial of AT278, its ultra-concentrated (500 U/mL), ultra-rapid acting insulin product candidate.

Arecor announces transfer of AT307 to Hikma

12/01/2023

Arecor is pleased to announce a key advancement in the development of AT307, a ready-to-use (“RTU”) injectable medicine, with the transfer of development activities and achievement of the next license milestone under the co-development and license agreement with Hikma.

Diagnostics for the Real World’s landmark SAMBA machine enters Science Museum Group’s permanent collection and features in major new “Injecting Hope” exhibition

02/12/2022

Breakthrough SAMBA II point-of-care diagnostic machine on show to the public from this November, as part of inspiring COVID-19 science showcase.

Arecor granted key patent in Japan and South Korea to protect proprietary insulin products AT247 and AT278

28/11/2022

Arecor is pleased to announce that the Japan Patent Office has granted a patent (JP7145849) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278. The same patent has also been granted in South Korea.

Arecor to commence second clinical trial with AT278 ultra-concentrated ultra-rapid acting insulin candidate for type 2 diabetes

28/11/2022

Arecor today announces the BASG (Bundesamt für Sicherheit im Gesundheitswesen) clearance of the Group’s Clinical Trial Application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population.

Arecor announces exclusive specialty hospital formulation collaboration

16/11/2022

Arecor Therapeutics today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies.

Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247

11/10/2022

Arecor Therapeutics today announces headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas.

New East of England children’s palliative care service launched

26/09/2022

A new palliative care service for babies, children and young people, including support for families, launched today (26 Sept) at Cambridge University Hospitals NHS Foundation Trust (CUH). The Park was delighted to host the launch of this new service at The Nucleus.

Anti-inflammatory drug candidate DMXD-011 shows efficacy in ex-vivo human studies

14/09/2022

Domainex is a leading provider of integrated drug discovery services. As a result of the work carried out by Domainex during an in-house research programme to identify inhibitors of protein kinases TBK1 and IKK-epsilon, DMXD-011 has been nominated as a preclinical drug candidate.

Chesterford Research Park welcomes ambitious new biotech firm

22/08/2022

Chesterford Research Park has announced that Constructive Bio has joined the Park’s highly regarded multi-occupier R&D building, Science Village.

Constructive Bio launches with $15M seed investment to re-engineer biology, creating new classes of enzymes, pharmaceuticals and biomaterials

16/08/2022

Constructive Bio today announces its launch as a new UK-based biotechnology company following the completion of a $15 million seed round and an exclusive license from the Medical Research Council.

Arecor granted European patents protecting proprietary formulations of high concentration Humira® biosimilar

09/08/2022

Arecor is pleased to announce that the European Patent Office has granted two patents (EP3592383B1 and EP3592385B1) protecting the Group’s novel formulations of high-concentration adalimumab until 2038.

The Write Up: Park Newsletter Summer 2022

09/08/2022

In this summer edition of the newsletter we explore the exciting new developments at the Park and celebrate current occupier successes. We are also delighted to welcome some new faces and we say a heartfelt farewell to others.

AI-powered drug discovery company Healx opens new labs at Chesterford Research Park

12/07/2022

Chesterford Research Park is delighted to welcome Healx to the Park’s prestigious Science Village.

Arecor announces presentation at EASD 2022 of Phase I clinical trial of AT278 ultra-concentrated ultra-rapid acting insulin for diabetes

04/07/2022

Arecor Therapeutics today announces that its abstract titled “Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500” has been selected for presentation at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting.

NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project

30/06/2022

NRG Therapeutics and Domainex today announce a collaboration focused on developing novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.

Proposals for brand new R&D building at Chesterford Research Park revealed

23/06/2022

The development will provide much needed accommodation to the burgeoning life science community within the Cambridge Cluster.

Arecor announces exclusive collaboration with a top 5 global pharmaceutical company

16/06/2022

Arecor Therapeutics today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.

New Allergyfocus Test From Oncologica Identifies Over 99% of Common Allergies

10/06/2022

Oncologica has launched a new Allergyfocus test that helps sufferers discover what common global allergens their bodies react to.

Diagnostics for the Real World (DRW) achieves UK technical validation for two multiplex respiratory virus rapid tests

18/05/2022

New combined tests deliver highly accurate point-of-care detection for SARS-CoV-2, Flu A, Flu B and RSV – boosting infection control in hospitals and speeding patient access to urgent care.

Winners of the Cambridge Independent Science and Technology Awards 2022 revealed

13/05/2022

A celebration of the extraordinary talent across a host of science and technology sectors was held at Hinxton Hall, on the Wellcome Genome Campus, on Wednesday evening (May 11).

Arecor presents full data from positive Phase I clinical trial at ATTD Meeting

28/04/2022

Arecor presents full data from positive Phase I clinical trial of AT278 ultra-concentrated ultra-rapid acting insulin for diabetes at ATTD Meeting.

Arecor announces oral presentation at ATTD 2022

12/04/2022

Arecor Therapeutics today announces that its abstract titled “AT278 (U500) – PK/PD and safety of rapid-acting concentrated insulin aspart”, has been selected for oral presentation at the upcoming 15th International Conference on Advanced Technologies and Treatments For Diabetes (ATTD) meeting.

New Research Findings by Oncologica on Detection of Brain Cancer Biomarkers

28/03/2022

New research findings on detection of brain cancer biomarkers by genomic sequencing aids clinical management for improved survival outcomes.

Arecor wins Innovation in Business and Business Person of the Year awards at the CambridgeshireLive Business Awards

28/03/2022

Arecor Therapeutics today announces that Arecor has won the HCR Hewitsons Award for Innovation in Business, and CEO, Sarah Howell, has won Business Person of the Year at the UK CambridgeshireLive Business Awards.

Arecor granted key U.S. patent protecting proprietary insulin products

24/03/2022

Arecor Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278.

Chesterford Research Park: Wellbeing Event, Thursday 10th March

18/03/2022

On Thursday, March 10th, Chesterford Research Park was an oasis of calm as it hosted a Park ‘Wellbeing’ event.

Microbiotica raises £50M ($67M) to advance pipeline of microbiome-based therapeutics

09/03/2022

Microbiotica today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.

Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park

28/02/2022

Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village.

Parkinson’s UK collaborates with Domainex on £3m project

08/02/2022

Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Cambridge company Domainex, have revealed a game-changing collaboration.

CellCentric secures investment from the American Cancer Society’s impact venture capital fund

26/01/2022

Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers. Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials.

Arecor commences US Phase I Clinical Trial

20/01/2022

Arecor today announces that it has commenced the US Phase I clinical trial of Arecor’s lead product, AT247, an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of three days.

Arecor announces exclusive collaboration with global technology leader

14/12/2021

Arecor Therapeutics today announces that it has signed an exclusive formulation study collaboration.

Arecor granted key Canadian patent for proprietary technology enabling highly concentrated biotherapeutics

11/11/2021

Arecor Therapeutics continues to build a strong patent portfolio protecting its proprietary Arestat™ technology.

NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study

10/11/2021

NodThera today announced that the first healthy volunteers have been dosed in a Phase 1 clinical trial of its lead investigational candidate, NT-0796.

CellCentric expands presence at Chesterford Research Park

08/11/2021

Chesterford Research Park is delighted to announce the expansion of existing occupier, CellCentric, within the Mansion House at the heart of the Park.

Arecor announces an executive formulation study collaboration with a leading global medical products company

04/11/2021

Arecor Therapeutics, the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.

Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platform

03/11/2021

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million.

Showcase your work – enter the Cambridge Independent Science and Technology Awards

03/11/2021

The highlight of the Cambridge science and technology scene is upon us. Entries are open for the 2021-22 Cambridge Independent Science and Technology Awards and we’re proud to once again be involved as a sponsor.

Breakthrough energy storage and R&D company Superdielectrics expands at Chesterford Research Park

24/09/2021

Chesterford Research Park is delighted to announce the expansion of an existing occupier, SuperDielectrics, into new laboratory and write up space within the Emmanuel Building.

Arecor announces positive headline results from first Phase I clinical trial of diabetes treatment

20/09/2021

Arecor Therapeutics today announces that its ultra-concentrated ultra-rapid acting insulin, AT278 met all of its primary and secondary endpoints with positive headline results from the Phase I clinical trial.

Exclusive formulation collaboration with Intas Pharmaceuticals Ltd

07/09/2021

Arecor Therapeutics, the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd (“Intas”).

Proclinical expands in California with San Diego office launch

02/09/2021

International life sciences staffing solutions provider, Proclinical, continues to rapidly expand its US business, with the recent announcement of a new office in San Diego, California.

COVID Vaccination, PCR testing and Variant Sequencing: The Key to Safe Cross-Border Travel

16/08/2021

With many people ditching staycations for trips overseas, the risk of traveller related introduction of high-risk COVID19 variants into the UK is a major issue surrounding European and international holiday travel.

Mestag Therapeutics extends seed financing to $45million and welcomes new investors Forbion, GV (formerly Google Ventures) and Northpond Ventures

03/08/2021

Mestag Therapeutics today announced the closing of its oversubscribed Seed extension.

Oxford Nanopore welcomes Wendy Becker and Adrian Hennah to Board

30/06/2021

Oxford Nanopore Technologies is pleased to announce the appointment of Wendy Becker and Adrian Hennah to its Board as Independent Non-Executive Directors, with effect from 24th June 2021.

Dr Bill Eldridge promoted to CSO

10/06/2021

Isogenica Ltd, a leader in the use of synthetic biology and in vitro display for the discovery and optimisation of novel biotherapeutics, announced today that Dr William (Bill) Eldridge has been promoted to Chief Scientific Officer.

Arecor appoints Dr. Lindsey Foulkes as Chief Operating Officer

10/06/2021

Arecor Therapeutics today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.

Exclusive formulation study collaboration with par sterile products to develop a stable ready to use product

10/06/2021

Arecor Therapeutics today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).

Arecor market cap soars to c$100m after IPO

09/06/2021

Cambridge biopharma business Arecor made a stunning bow on London’s AIM market today as its share price immediately grew wings.

Arecor announces an exclusive formulation study collaboration with Lilly

21/05/2021

Arecor, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study partnership with Eli Lilly and Company (“Lilly”).

Arecor granted key US Patent

21/05/2021

Arecor today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology platform.

Arecor set for UK IPO

20/05/2021

Thrusting Cambridge biopharma business Arecor is planning a UK IPO. The company is advancing a robust portfolio of partnered and proprietary treatments from existing therapies to enable healthier lives. Diabetes is a prime area.

CellCentric expands trials of cancer drug into US

12/05/2021

Cambridge biotech company, CellCentric is expanding clinical trials of its potential cancer drug into the US.

Newborn bio business Mestag Therapeutics raises $11m seed cash

28/04/2021

A new Cambridge UK BioMedTech business fighting inflammatory disease and cancer launched today with $11 million seed cash from healthcare backers SV Health Investors and Johnson & Johnson Innovation.

The Write Up: Park Newsletter Spring 2021

27/04/2021

In this Spring edition of the Park newsletter we celebrate current occupier successes and are delighted to welcome some new faces too. We also highlight some of the outdoor activities and classes that are open to all to enjoy!

Microbiotica moves into new building at Chesterford Research Park

19/04/2021

Microbiotica today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park to accommodate its long-term growth requirements.

London landlords will need to experiment with how they build and let lab space

16/04/2021

The latest Savills blog considers the creative lengths London landlords will have to go to develop attractive space for life science companies.

Oncologica is the First UK Genomic Testing Lab to Be Government Approved for Day 2 and Day 8 Testing

01/04/2021

Oncologica is pleased to announce that its Cambridge based testing laboratory is now the first UK laboratory to receive approval by UKAS and the Department of Health and Social Care (DHSC) to perform Covid PCR testing requirements for day 2 and day 8.

Arecor receives £2.8 million grant award from Innovate UK

01/04/2021

Arecor today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.

Axol Bioscience and Censo Biotechnologies Announce Merger

17/03/2021

Axol Bioscience and CENSO Biotechnologies today announced that the two companies have signed a merger agreement.

Microbiotica Appoints Hans Schikan as Independent Non-Executive Chairman

24/02/2021

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Hans Schikan as Non-Executive Chairman, effective immediately.

Synthetic biology company, Camena Bioscience, expands presence at Chesterford Research Park

22/02/2021

Chesterford Research Park is delighted to confirm the expansion of Camena Bioscience within the Science Village Building at the Park.

Clean-tech company Superdielectrics relocates to Chesterford Research Park

15/02/2021

The sustainable electrical energy storage specialist secures Suite 2 in the Science Village.

Microbiotica expands management team with appointments of Chief Medical Officer and Chief Operating Officer

10/02/2021

Microbiotica today announces the appointment of Ronald Carter, MD, as Chief Medical Officer (CMO), and the appointment of Tim Sharpington as Chief Operating Officer (COO).

Building Life Science Adventures - Careers Conference 2021

30/03/2021

Join us at One Nucleus for our first ever Careers Conference on 30th and 31st March 2021.

Isogenica multi-year multi-target collaboration with Aro Biotherapeutics extended

19/01/2021

Isogenica announced today that it has extended its multi-year, multi-target collaboration and license agreement with Aro Biotherapeutics.

The 21 European Biotech Companies to Watch in 2021

15/01/2021

Chesterford Research Park based biotech NodThera has made the list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year.

CellCentric’s first-in-class p300/CBP inhibitor CCS1477 publishes in Cancer Discovery

12/01/2021

CellCentric has developed the first p300/CBP inhibitor of its kind, to treat targeted types of cancer.

NodThera strengthens C-level team to advance fight against inflammatory disease

11/01/2021

Cambridge biotech NodThera, which raised a stunning $55 million Series B last summer, has made two high-level hires as it advances a new class of medicines to fight chronic inflammation.

Chesterford addresses need for laboratory space in Cambridge Cluster

18/12/2020

Having completed the transformation of the Newnham Building into fully-fitted laboratory and office accommodation earlier this month, the team at Chesterford has swiftly moved on to its next project, the refurbishment of the Emmanuel Building.

A tale of two halves for commercial property market

18/12/2020

This year has been a tale of two halves for the commercial property market. Whilst the industrial and R&D sectors have seen significant value increases, unsurprisingly the retail and investment markets have struggled to keep up the pace.

Arecor’s partner Inhibrx exercises its option to licence a new formulation developed by Arecor

17/12/2020

Arecor today announces that its partner, Inhibrx, has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.

Arecor Announces Publication of Phase I Data for AT247 in Diabetes care

16/12/2020

Arecor today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

First Patient Dosed in Phase 1 Clinical Trial of Ultra-concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes

15/12/2020

Arecor announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

11/11/2020

APEIRON Biologics AG has selected Domainex Ltd to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery.

Cambridge Independent Science and Technology Awards 2020 Finalists Revealed

11/11/2020

The finalists for the Cambridge Independent Science and Technology Awards 2020 represents an incredible array of talent from the Cambridge area in fields from biotech and medtech to AI and cleantech.

CellCentric raises $33m to broaden clinical trials of its first-in-class p300/CBP inhibitor, CCS1477

22/10/2020

CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with specific drivers (AR, MYC, or p300/CBP mutations).

Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine

20/10/2020

Hikma Pharmaceuticals today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.

Oncologica secures last available state of the art laboratory suite within the Newnham Building

05/10/2020

Chesterford Research Park is delighted to confirm that Oncologica has secured the last available suite within the newly re-configured Newnham building at the Park and will take up occupancy with immediate effect post partial practical completion, which is due within the next week.

Arecor to present at European Association for the Study of Diabetes (EASD) 2020

21/09/2020

Arecor today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for presentation at the upcoming EASD virtual meeting.

Taylor-made: Great things expected of Axol’s new CEO

26/08/2020

Human cell technology business Axol Bioscience has a new CEO to steer the next phase of global growth from its Cambridge UK and Massachusetts US facilities.

Diagnostics for the Real World: The team behind rapid COVID-19 test deal with growth and look to the future

12/08/2020

Diagnostics for the Real World (DRW) made worldwide headlines earlier this year with a game-changing way of testing for COVID-19 that was rolled out to the NHS after being first used at Addenbrooke’s Hospital.

Inventive use of space allows Diagnostics for the Real World to keep on top of demand for COVID-19 test kits

06/08/2020

Chesterford Research Park based Diagnostics for the Real World (DRW) made worldwide headlines earlier this year with a game-changing way of testing for COVID-19.

Oxford Nanopore Technologies partners with UK Government to roll out LamPORE, a new generation of COVID-19 test

05/08/2020

Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test.

Invivoscribe licenses small molecule inhibitors from Domainex to treat acute myeloid leukemia

16/07/2020

Invivoscribe announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities to accelerate drug development.

Cambridge scientist-turned-recruiter boosts Proclinical team

18/06/2020

Global life sciences recruitment and consulting business, Proclinical, has added significant gravitas to its Cambridge-based executive search team.

Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin

16/06/2020

Arecor presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, at the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting. The abstract, #231-OR, is available on the ADA website.

Arecor announces oral presentation at the ADA 80th scientific sessions

11/06/2020

Arecor today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting.

NodThera Announces Close of $55 Million Series B Financing

04/06/2020

NodThera, a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, today announced that it has secured $55 million (£44 million) in a Series B financing.

Domainex announces the appointment of Dr. Eddy Littler as non-executive Chairman

04/06/2020

Following the retirement of Tony Brampton, Eddy Littler has been appointed as non-executive Chairman of Domainex Ltd.

How Covid-19 is affecting the labs and life science firms combatting the outbreak

24/04/2020

The life science sector has received increased attention from real estate investors and developers recently, with new entrants to the UK market joining a handful of rapidly expanding established players.

BLOG: Targeting P300/CBP through to specific oncology applications

16/04/2020

CellCentric’s CCS1477 programme targets specific gene and protein regulatory mechanisms of action with a highly potent, selective small molecule inhibitor.

CellCentric signs agreement with the PCCTC for Phase II clinical trial expansion into the US

09/04/2020

CellCentric has developed CCS1477, the first p300/CBP inhibitor of its kind, for use in the treatment of multiple cancer types.

Diagnostics for the Real World rapid COVID-19 test rolled out to NHS

03/04/2020

Park occupiers Diagnostics for the Real World (DRW) has developed a test for COVID-19 which has been described as ‘game-changing’ thanks to the speed at which it delivers results.

Arecor targets oncology and rare orphan diseases in US alliance

20/03/2020

Cambridge biopharma business Arecor has extended its multi-product collaboration with a US-based clinical stage biotechnology company.

Proclinical Launches UK Satellite Office at Chesterford Research Park

20/03/2020

Global life sciences recruitment and consulting business, Proclinical, announced the launch of its latest new office this week, located at Chesterford Research Park.

Arecor achieves second license milestone payment from global pharmaceutical partner

25/02/2020

Arecor Ltd today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners.

LUNAC Therapeutics selects Domainex as its strategic drug discovery partner

25/02/2020

Domainex Ltd has entered into a research partnership with LUNAC Therapeutics Limited to discover novel anticoagulant therapies that have a reduced risk of bleeding compared to current therapies.

Laboratory space take-up rockets in Cambridge

18/02/2020

Take-up of laboratory space in Cambridge was 10 times higher in 2019, jumping from 17,145 sq ft in 2018 to more than 214,100 sq ft. This equates to 29 pr cent of all commercial property transactions over the past 12 months, according to Savills research.

Domainex announces the appointment of Tom Mander as Chief Executive Officer

13/02/2020

Domainex Ltd is pleased to announce the appointment of Dr Tom Mander as Chief Executive Officer. Dr Mander will take over when Dr Trevor Perrior retires from the role in April 2020.

Isogenica adds to leadership team and announces deal with Nasdaq company

05/02/2020

Isogenica in Cambridge has made two leadership appointments to extend and accelerate its partnerships and pipeline of therapeutic assets and provide a strong foundation for future growth.

Isogenica announces multimillion-pound agreement with recently nasdaq listed Biontech SE

09/01/2020

Isogenica has entered into a multi-target, multi-year partnership with BioNTech.

Hikma and Arecor announce exclusive agreement

09/01/2020

Hikma Pharmaceuticals and Arecor Ltd today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.

Microbiotica relocates to Chesterford Research Park, Cambridge

19/11/2019

Chesterford Research Park and Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announce that Microbiotica is relocating to the Park in a two-phase move that will be completed in June 2020.

Arecor to present at the Sixth China Healthcare Summit 2019 in Shanghai, China

19/11/2019

Arecor announces that its Chief Executive Officer, Dr Sarah Howell, will present at The Sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.

Winners of the Cambridge Independent Science and Technology Awards 2019 revealed

05/11/2019

The winners of the Cambridge Independent Science and Technology Awards 2019 have been revealed at a packed ceremony at The Bradfield Centre on Cambridge Science Park.

Appointment of Jim MacDonald-Clink as Vice President, Business Development

01/11/2019

Arecor today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.

Arecor and JDRF sign a joint research, development and commercialisation agreement

25/10/2019

Arecor announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research.

Isogenica appoints Dr Bjӧrn Cochlovius to Board of Directors

16/10/2019

Isogenica today announced the appointment of Dr Bjӧrn Cochlovius to Isogenica’s Board of Directors (the “Board”) effective immediately.

Dosing complete in Phase 1 Clinical Trial of Ultra-Rapid acting Insulin Product Candidate AT247 for Diabetes

09/10/2019

Arecor Limited today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.

The Rise of Epigenetics

19/09/2019

Heather Tudor, Director of Quality Assurance at Cambridge Epigenetix spoke with Quality World magazine about the use of quality principles to enhance human health.

Pioneering Chesterford Research Park occupiers feature in Cambridge science and tech awards shortlist

19/09/2019

Chesterford-based NodThera and Cambridge Epigenetix have been named as finalists in the Cambridge Independent Science and Technology Awards 2019.

2019 Cambridge Independent Science and Technology Awards

13/09/2019

The finalists in this year’s Cambridge Independent Science and Technology Awards have been revealed. Find out which Park Occupiers made the shortlist.

Grass Valley Launches Kula AV at IBC 2019

13/09/2019

Grass Valley will unveil Kula AV, a powerful, multiformat all-in-one system that mixes video and digital audio, includes full clip-store integration to graphics creation and editing, and provides built-in multiviewer capability.

Sunday Times Tech Track 100

13/09/2019

Park Occupier Oxford Nanopore placed within the top ten of the Sunday Times Tech Track 100.

Charles River Laboratories updates microbial solutions portfolio

13/09/2019

Charles River Laboratories has announced the launch of two new products in its Microbial Solutions portfolio.

CellCentric starts dosing patients in blood cancer trial, expanding clinical testing of CCS1477

13/09/2019

CellCentric has expanded the clinical development programme of its novel anti-cancer drug CCS1477.

Arecor welcomes discussion with Mrs Kemi Badenoch, MP for Saffron Walden

06/08/2019

Arecor welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.

Lonza Pharma & Biotech chooses Chesterford Research Park to expand UK operations

06/08/2019

Lonza signs 15-year lease of the 42,000 sq ft Gonville Building at Chesterford Research Park.

Isomerase secures first pre-let within the Newnham Building

16/07/2019

Chesterford Research Park is delighted to confirm that Isomerase will take up occupancy within Suite 4 of the Newnham Building upon its completion in mid 2020.

Synthetic biology gets a makeover with Evonetix’s DNA synthesis technology

09/07/2019

Interview with Matthew Hayes, CTO and Co-Founder, Evonetix

Boston research firm leads the charge to Cambridge

05/07/2019

Property adviser Savills reports a fresh surge of interest in Cambridge from American companies and investors.

Global double whammy for fast-growing Arecor

15/05/2019

A global top 20 pharmaceutical giant is leveraging proprietary formulation technology from Arecor, the Chesterford Research Park-based company.

Two honey bee hives arrive at Chesterford Research Park’s new apiary

08/05/2019

20,000 honey bees have a new home at the Park after three members of the team passed their bee-keeping course with flying colours!

Uttlesford District Council in running for award after investment in Chesterford Research Park

08/05/2019

Uttlesford District Council's (UDC) entrepreneurial activities have been short-listed for two major local government awards.

Domainex helping to develop potential new heart drug

07/05/2019

Domainex scientists, working with Professor Michael Schneider and his team at Imperial College, have found a potential new drug for treating the damage caused by a heart attack by targeting the way the heart reacts to stress.

NodThera advances lead candidate and adds two big hitters to board

07/05/2019

NodThera has advanced its lead development candidate, NT-0167, into pre-IND testing as it prepares to advance to the clinic.

Cambridge startups lead regional VC boom despite UK lull

07/05/2019

More than £125 million ($163.4m) of Venture Capital investment was made into the startup community in the East of England in the first three months of the year.

First patient dosing in Phase 1 Clinical Trial of Ultra-Rapid Acting Insulin Product Candidate AT247 for Diabetes

07/05/2019

Arecor today announces dosing of the first patient in its Phase 1 clinical trial for its ultra-rapid acting insulin product candidate, AT247.

CellCentric backed in blood cancers trials

03/05/2019

CellCentric in Cambridge has received approval from the UK regulatory authority, the MHRA, to start clinical trials of its CCS1477 technology to treat certain blood cancers.

Arecor signs a new multi-product collaboration with a major global pharmaceutical company

03/05/2019

Arecor today announces that it has signed a collaboration with a new major global pharmaceutical partner.

GrandOmics collaborates with Oxford Nanopore to deliver nanopore sequencing project dbSV-100k

25/04/2019

Strategic collaboration represents largest nanopore sequencing project to date.

Chesterford Research Park companies make their mark in Business Weekly’s Killer50 rankings

28/03/2019

Business Weekly has published its 2019 list of Cambridge’s most disruptive tech and life science companies, known as the ‘Killer50’.

Domainex and SpiroChem enter a fragment drug discovery partnership

20/03/2019

Domainex Ltd have established a strategic fragment drug discovery collaboration that they will co-promote globally.

Arecor receives Regulatory Approval to Initiate Phase 1 Clinical Trial for Ultra-Rapid Acting Insulin Product

20/03/2019

Arecor Ltd today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

Arecor Appoints Chief Financial Officer

11/03/2019

Arecor Limited is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.

International Women’s Day activities at Chesterford Research Park focus on empowering women to return to work

08/03/2019

Chesterford Research Park and Isogenica team up to host a clothing drive in aid of not-for-profit organisation, Dress for Success.

Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost

13/02/2019

Arecor Ltd has been awarded a £0.5 million grant from Innovate UK to advance the Company's proprietary super-fast-acting prandial insulin product, AT270.

Business Weekly New Year Honours 2019

17/01/2019

We're delighted to have been included in Business Weekly's New Year Honours Listing 2019. Discover where we placed in the following article.

Arecor Featured by Industry Publication SCRIP

24/01/2019

Arecor Ltd is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available on the news section of the company’s website.

Isogenica LlamdA VHH antibodies reported as a potential treatment of Wnt-hypersensitive tumours

23/01/2019

Isogenica Ltd today announced the publication in Nature Communications of a promising new strategy for treatment of Wnt-hypersensitive tumours.

Evonetix appoints Stephanie Brooking as Head of Product Management

14/01/2019

Evonetix Ltd today announced it has appointed Stephanie Brooking as Head of Product Management.

Illumina CEO talks $100 genome, tariffs and NovaSeq at JP Morgan

10/01/2019

CEO Francis deSouza discusses the $100 genome, tariffs and NovaSeq and other topics during Illumina’s JP Morgan presentation and breakout session.

Arecor to participate at PEPTalk 2019 protein science week in San Diego

09/01/2019

Arecor is pleased to announce its participation at PEPTalk 2019’s Protein Science Week, January 14018, 2019, San Diego, California, USA.

Arecor announce clinical trials application to conduct a Phase I clinical trial of its ultra rapid acting insulin product

04/01/2019

Arecor has filed a Clinical Trial Application to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin product, AT247.

Can Cambridge become the world's leading biotech cluster?

11/12/2018

The fenland city has big plans for its £4.2bn life sciences hub, but without support it will struggle to match the scale of world-leader Boston.

Occupier Focus: Charles River Laboratories

29/11/2018

From prestigious, bespoke HQ buildings, to the fully fitted laboratory space Chesterford Research Park offers biotechnology and pharmaceutical R&D companies modern, dynamic and flexible facilities.

Arecor successfully defends key European Patent

30/10/2018

Arecor successfully defends a key European Patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage.

Spotlight on the Newnham Building

04/10/2018

Occupying a prominent position on the park and within close reach of the Nucleus’ central facilities, the existing Newnham building is set to undergo an extensive programme of refurbishment.

Arecor secures £6m investment for clinical development of portfolio

10/09/2018

Arecor today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development.

Occupier focus: Arecor

06/09/2018

One organisation which has been thriving at Chesterford is Arecor Limited, a leading formulation technology company.

Arecor presenting at the Bioprocessing Summit, Boston, MA

09/08/2018

Arecor Ltd is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.

NodThera secures £28 million ($40 million) Series A Financing

25/06/2018

NodThera today announces it has closed its Series A financing round for a total of £28 million ($40 million).

Arecor announces superfast insulin data

21/06/2018

Arecor announces superfast insulin data presentations at the American Diabetes Association 78th Scientific Sessions.

Chesterford Research Park – positioned for success

03/05/2018

Chesterford Research Park has established itself as a centre of excellence within the South Cambridge biotech cluster, providing a supportive and nurturing location for innovation.

US$1.3 MILLION* Grant awarded to Arecor & Manchester Institute of Biotechnology

22/06/2018

Arecor Ltd is pleased to announce that the Company, in collaboration with the Manchester Institute of Biotechnology (“MIB”), has been awarded a £0.97 million grant from Innovate UK.

Arecor Patent Portfolio Update

01/05/2018

Arecor Ltd has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of protein therapeutics.

A superb environment for both early stage and established R&D companies

05/04/2018

Providing the very best flexible and future proofed environment for both established and early stage companies, Chesterford actively facilitates occupiers’ pursuit of their research.

Discover a new future at Chesterford Research Park

25/01/2018

Chesterford Research Park provides a full range of facilities and an exceptional working environment for both established and early-stage pharmaceutical and R&D companies.

Arecor and JDRF announce successful pre-clinical development

04/01/2018

Arecor and JDRF are pleased to announce the successful completion of their partnered programme to significantly enhance treatment of type 1 diabetes.

Arecor announces successful vaccine stabilising formulation technology

08/12/2017

Arecor in partnership with GALVmed has successfully applied its vaccine formulation technology to stabilise liquid formulations of vaccines to combat two major diseases of livestock in the developing world.

Fundraising efforts raise over £700 for Children In Need!

17/11/2017

The Park Team took fundraising for Children In Need incredibly seriously on Friday last week - dressing the part as well-known characters to raise money for Pudsey!

Isomerase celebrate presentation of Queen’s Award for Enterprise

16/11/2017

Isomerase staff, guests and local dignitaries gathered to celebrate the organisation’s attainment of the Queen’s Award for Enterprise in International Trade.

Arecor strengthens patent portfolio

07/11/2017

Arecor strengthens the patent portfolio of its formulation technology for the development of novel vaccine and gene therapy products.

TLIP provides Patent Strategy Workshop to Isogenica

03/11/2017

TLIP has concluded a series of IP seminars for Isogenica, a company specialising in antibody discovery and other biologics using proprietary techniques.

Arecor announces license agreement with global pharmaceutical company

03/10/2017

Arecor is pleased to announce that a global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.

Dr Sam Fazeli joins Arecor as Non-Executive Director

07/09/2017

Arecor Ltd is pleased to announce the appointment of Dr Sam Fazeli, as Non-Executive Director of the Company.

Cambridge Epigenetix relocate to Chesterford Research Park

02/11/2017

Specialists in the discovery of epigenetic biomarkers and the development of clinical diagnostic assays take up residence in the Trinity Building.

CellCentric exploring CCS1477 and p300/CBP inhibition for haematological cancers

08/12/2017

CellCentric has signed an agreement with Columbia University Medical School, New York USA, to explore the relevance of the company’s drug Candidate, CCS1477, in treating certain haematological cancers.

Third place for Michael at World Championships!

28/08/2017

All the training is clearly paying off as Michael placed third in the Sprint Duathlon World Championships in Penticton, Canada during the ITU Multipart World Championships Festival.

Axol enhances its future scientific & commercial endeavours

22/08/2017

Axol Bioscience has received investment from private equity firm Calculus Capital, a leading EIS and VCT investor.

From Office Junior to Director...

28/07/2017

Cathy Mack has been appointed Director and Chief Operating Officer (COO) of patent and trademark company, TLIP Ltd (Turnbull Lynch Intellectual Property).

Cabinet members ‘meet and greet’ Park lifescience organisations

19/07/2017

Further to Uttlesford District Council’s recent purchase of a 50% share in Chesterford Research Park, members visited to tour the facilities of Arecor and Evonetix.

Isogenica announces renewal of licence agreement by Harpoon

23/05/2017

Isogenica Ltd today announced that Harpoon Therapeutics is renewing the licence and option agreement originally signed with Isogenica in June 2016.

Uttlesford District Council purchase 50% share in Park

16/05/2017

Local authority invests in prestigious development to become joint owners alongside Aviva Investors.

Isomerase win Queen's Award for Enterprise in International Trade

21/04/2017

Isomerase staff, guests and local dignitaries gathered to celebrate the organisation’s attainment of the Queen’s Award for Enterprise in International Trade.

Evonetix take two suites within Science Village

28/02/2017

The Start-up developing and commercialising a new approach to the synthesis of DNA has taken two suites in Science Village.

Isogenica: New licence agreement with top-25 global pharma company

21/02/2017

Isogenica Ltd today announced a new licensing deal with a top-25 global pharmaceutical company which specialises in immunology, oncology and immuno-oncology biopharmaceuticals.

CellCentric’s novel p300/CBP inhibitor, CCS1477 advancing to the clinic

16/02/2017

CellCentric has developed a potent, selective, orally bioavailable small molecule inhibitor of p300/CBP.

Isogenica announce new licensing deal with Maverick Therapeutics

06/02/2017

Science Village based Isogenica Ltd today announced a new licensing deal with Maverick Therapeutics.

Arecor awarded £1.05M from Innovate UK

02/02/2017

Arecor Ltd is pleased to announce that it has been awarded a £1.05 million grant from InnovateUK.

Enplas takes a suite within Science Village

21/11/2016

The Cambridge Enplas Life Science Laboratory, part of Enplas EU Ltd, a wholly owned subsidiary of Enplas Corporation have taken a five-year lease within the Park’s Science Village.

CamNet Data Communications relocate to Park

01/11/2016

Local data communications company moves to Chesterford to fuel future growth.

Arecor confirms move to Chesterford Research Park

13/09/2016

Chesterford Research Park attracts leader in formulation technology innovation, Arecor, to the Park.

Chesterford Research Park proves ideal new home for Domainex

12/09/2016

Provider of integrated drug discovery services benefits from enhanced space within the Churchill Building.

Mat Leese joins specialist European Patent Attorney, TLIP

27/07/2016

Mat joins TLIP as a UK and European Patent Attorney and has particular expertise in securing additional terms of protection for therapeutic products.

Axol Bioscience sign collaboration agreement with Metrion Biosciences

26/07/2016

The agreement aims to improve, standardise and more accurately predict the risk of human clinical proarrhythmias.

RPC take on further space within the Mansion House to support growing team

19/07/2016

Insurance sector specialists RPC Consulting take on further space within the Mansion House to support growing actuarial software team.

DRW's Helen Lee wins EPO European Inventor of the year award!

08/07/2016

Congratulations to Dr Helen Lee of DRW who has been awarded the European Inventor Award by the European Patent Office.

Michael wins Bronze at European Duathlon Champs!

05/05/2016

Congratulations to Michael Buchallet, who finished third in his age group at the European Duathlon (sprint) Championships in Germany last Saturday!

Park plants 2000 poppies to celebrate work of Royal British Legion

02/05/2016

Joined by the Mayor of Saffron Walden, Park occupiers, staff and guests help to plant a new poppy and wildflower meadow at Chesterford Research Park.

Axol Bioscience appoints Paul Andrews to Scientific Advisory Board

22/02/2016

Axol Bioscience today announced Paul Andrews as their Scientific Advisory Board Member.

Steve Rees joins Axol Bioscience Scientific Advisory Board

20/01/2016

Axol Bioscience have announced that Steve Rees of AstraZeneca will join their Scientific Advisory Board (SAB).

Axol Bioscience re-locate to Chesterford to facilitate future growth

12/01/2016

The stem cell disease model specialists join Chesterford’s Science Village community, taking space within the Park’s prestigious, ‘plug and play’ laboratory accommodation.

Collaboration with Cambridge Enterprise highlights thriving life science community

01/10/2015

Over 70 top academics from Poland visited the Park as part of nine week ‘Top 500 Innovators’ programme.

Oncologica's success drives expansion at the Park

24/09/2015

Oncologica take a further suite within The Science Village, Chesterford’s high quality, prestigious self-contained accommodation.

The European patent and trademark attorney joins Mansion House

20/08/2015

Chesterford Research Park is delighted to welcome TLIP (Turnbull Lynch Intellectual Property) to the Park.

Park sponsored duathlete, Michael Buchallet, competes in Spain

06/07/2015

Michael ran strongly over the first 5km before coming in to collect his bike for two laps of the difficult course.

Oncologica choose Chesterford Research Park as location for new HQ

11/03/2015

The Contract Research and Diagnostic Services organisation take a suite in Science Village, Chesterford’s high quality, prestigious self-contained accommodation.

Park backs Team GB Duathlete, Michael Buchallet

02/03/2015

Park’s health and fitness centre, situated within The Nucleus central facilities building at the heart of the Park, offers Michael training support.

Chesterford Research Park welcome Quantel to Science Village

12/02/2015

Leading developer of innovative, high performance media content creation and delivery systems joins swiftly expanding Science Village community on the Park.

Park welcome Diagnostics for the Real World to Science Village

02/02/2015

Leading developer and supplier of breakthrough point-of-care diagnostics is the latest company to take up occupancy within the Science Village Building.

Race to Lapland challenge inspires Nucleus gym members!

12/01/2015

Race to Lapland challenge inspires Nucleus gym members!

Christmas comes early to Chesterford Research Park!

01/12/2014

Despite the rain 75 Park tenants and members of the local community gathered at Chesterford Research Park this lunchtime to take part in a Santa Fun Run.

Chesterford Research Park Team out in force for Children in Need

14/11/2014

Today the Park Team are once again dressed in their finest in support of Children in Need.

Isomerase Therapeutics expands presence within Science Village

07/10/2014

Innovative drug discovery and development company take additional Suite within the Science Village Building.

Park helps raise over £3,000 for Addenbrooke’s Breast Cancer Appeal

01/10/2014

Wednesday 1st October Chesterford Reseach Park played host to a very special fashion show in aid of Addenbrooke’s Breast Cancer Appeal.

Biofocus win Chesterford’s 5-a-side tournament

30/09/2014

The team beat off stiff competition over the course of the tournament from Illumina, SBS, and Glassworks but ultimately came out on top.

Isogenica appoints new CEO

29/09/2014

Isogenica have announced the appointment of Dr Chris Ullman as CEO with effect from September 29th 2014.

Marriott Sinclair move to Chesterford Research Park

01/09/2014

Mathematical modelling company take remaining space within Garden Cottage.

Excitement as Tour de France cyclists pass through Chesterford!

18/08/2014

Le Tour comes to Chesterford!

Carnival Celebrations at The Nucleus to mark local residents' 50th birthday!

18/08/2014

All the fun and colour of the carnival came to The Nucleus last Saturday night to celebrate a local Little Chesterford residents’ 50th birthday.

Cambridge Architects Barber Casanovas Ruffles celebrate 30th year

11/07/2014

Clients, colleagues and friends gather to mark leading architects 30th anniversary.

Retroscreen Virology to occupy Emmanuel Building at Chesterford Research Park

30/06/2014

Antiviral research company, Retroscreen Virology has completed a deal to assign the entire Emmanuel building from current occupiers, Pfizer.

Park raises much needed funds for Teenage Cancer Trust

02/06/2014

Chesterford Research Park held a pre-Christmas raffle, the proceeds of which will help the charity continue to support and educate young people affected by cancer and fund further research.

Construction underway for BioFocus’ new laboratory and HQ facility

26/05/2014

BioFocus management team celebrate commencement of works with first site visit.

Greentech technology company Cellulac move into the Science Village

14/04/2014

The Park has welcomed yet another innovator, this time to Science Village. Cellulac, a ‘greentech’, carbon neutral technology company has taken Suite 4 (1,515 sq ft) on a five year lease.

Celebrity Chef Anton Edelmann delights Park guests with Autumnal celebration

03/10/2013

Commercial agents, Park tenants, Investors, joint developers of the Park, as well as special guests from Elior, the Park’s contract caterers, gathered at The Nucleus for an evening of exceptional gourmet food and fine wines.

Saffron Building Society expands to Chesterford

09/09/2013

A former engineering building at Chesterford Research Park has been converted and renovated to provide a new home for the Contact Centre team from Saffron Building Society.